Stay updated on SMT-NK with Pembrolizumab in Biliary Tract Cancer Clinical Trial
Sign up to get notified when there's something new on the SMT-NK with Pembrolizumab in Biliary Tract Cancer Clinical Trial page.

Latest updates to the SMT-NK with Pembrolizumab in Biliary Tract Cancer Clinical Trial page
- Check4 days agoChange DetectedThe record presents details of a completed Phase 1/2a study of allogeneic NK cells combined with pembrolizumab for advanced biliary tract cancer, including its design, participant criteria, and measured outcomes.SummaryDifference47%

- Check11 days agoChange DetectedThe displayed ClinicalTrials.gov site revision changed from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedA sitewide NIH notice announces a transition from “Artificial Intelligence” to “Super Intelligence” terminology. The footer revision changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check39 days agoChange DetectedThe site footer revision changed from v3.7.0 to v3.7.1 while the page continued to display a 403 error.SummaryDifference0.2%

- Check53 days agoChange DetectedThe page displays a 403 Forbidden error instead of the study record, with the previous study content removed and a Home link shown.SummaryDifference18%

- Check60 days agoChange DetectedRevision updated from v3.6.6 to v3.7.0, reflecting a new published version of the page’s documentation.SummaryDifference0.1%

Stay in the know with updates to SMT-NK with Pembrolizumab in Biliary Tract Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SMT-NK with Pembrolizumab in Biliary Tract Cancer Clinical Trial page.